The stock price of ProKidney Corp (NASDAQ: PROK) has dropped by -10.40 compared to previous close of 2.50. Despite this, the company has seen a gain of 0.45% in its stock price over the last five trading days. zacks.com reported 2024-06-21 that Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.
Is It Worth Investing in ProKidney Corp (NASDAQ: PROK) Right Now?
The stock has a 36-month beta value of 1.30. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PROK is 68.39M, and at present, short sellers hold a 14.88% of that float. On July 03, 2024, the average trading volume of PROK was 1.04M shares.
PROK’s Market Performance
PROK’s stock has seen a 0.45% increase for the week, with a -35.63% drop in the past month and a 51.86% gain in the past quarter. The volatility ratio for the week is 10.37%, and the volatility levels for the past 30 days are at 16.96% for ProKidney Corp The simple moving average for the past 20 days is -19.55% for PROK’s stock, with a -1.99% simple moving average for the past 200 days.
Analysts’ Opinion of PROK
Many brokerage firms have already submitted their reports for PROK stocks, with Morgan Stanley repeating the rating for PROK by listing it as a “Equal-Weight.” The predicted price for PROK in the upcoming period, according to Morgan Stanley is $3 based on the research report published on March 07, 2024 of the current year 2024.
BTIG Research gave a rating of “Buy” to PROK, setting the target price at $16 in the report published on July 25th of the previous year.
PROK Trading at -23.42% from the 50-Day Moving Average
After a stumble in the market that brought PROK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.42% of loss for the given period.
Volatility was left at 16.96%, however, over the last 30 days, the volatility rate increased by 10.37%, as shares sank -26.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.80% upper at present.
During the last 5 trading sessions, PROK rose by +0.45%, which changed the moving average for the period of 200-days by -67.82% in comparison to the 20-day moving average, which settled at $2.75. In addition, ProKidney Corp saw 25.84% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROK starting from Weber Darin J., who sale 17,238 shares at the price of $2.82 back on Jun 18 ’24. After this action, Weber Darin J. now owns 120,718 shares of ProKidney Corp, valued at $48,616 using the latest closing price.
Legorreta Pablo G., the Director of ProKidney Corp, purchase 22,617,909 shares at $2.42 during a trade that took place back on Jun 13 ’24, which means that Legorreta Pablo G. is holding 22,617,909 shares at $54,735,340 based on the most recent closing price.
Stock Fundamentals for PROK
Current profitability levels for the company are sitting at:
- -29.86 for the present operating margin
- 0.24 for the gross margin
The net margin for ProKidney Corp stands at -12.31. The total capital return value is set at -0.36.
Based on ProKidney Corp (PROK), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.59. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -19171.29.
Currently, EBITDA for the company is -148.35 million with net debt to EBITDA at 0.62. When we switch over and look at the enterprise to sales, we see a ratio of 124.81. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.62.
Conclusion
To sum up, ProKidney Corp (PROK) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
